X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC LTD with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD vs DR. REDDYS LAB - Comparison Results

ALEMBIC LTD    Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC LTD DR. REDDYS LAB ALEMBIC LTD/
DR. REDDYS LAB
 
P/E (TTM) x 123.1 30.5 403.6% View Chart
P/BV x 4.6 3.0 153.0% View Chart
Dividend Yield % 0.2 0.9 27.1%  

Financials

 ALEMBIC LTD   DR. REDDYS LAB
EQUITY SHARE DATA
    ALEMBIC LTD
Mar-16
DR. REDDYS LAB
Mar-17
ALEMBIC LTD/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs533,397 1.6%   
Low Rs292,560 1.1%   
Sales per share (Unadj.) Rs4.7856.5 0.6%  
Earnings per share (Unadj.) Rs8.878.0 11.3%  
Cash flow per share (Unadj.) Rs9.0139.9 6.4%  
Dividends per share (Unadj.) Rs0.1520.00 0.8%  
Dividend yield (eoy) %0.40.7 54.4%  
Book value per share (Unadj.) Rs27.7739.8 3.7%  
Shares outstanding (eoy) m267.03165.74 161.1%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x8.73.5 250.1%   
Avg P/E ratio x4.738.2 12.2%  
P/CF ratio (eoy) x4.621.3 21.4%  
Price / Book Value ratio x1.54.0 36.8%  
Dividend payout %1.725.7 6.7%   
Avg Mkt Cap Rs m10,962493,632 2.2%   
No. of employees `000NA22.7 0.0%   
Total wages/salary Rs m23831,068 0.8%   
Avg. sales/employee Rs ThNM6,259.0-  
Avg. wages/employee Rs ThNM1,369.8-  
Avg. net profit/employee Rs ThNM569.7-  
INCOME DATA
Net Sales Rs m1,260141,961 0.9%  
Other income Rs m2641,715 15.4%   
Total revenues Rs m1,524143,676 1.1%   
Gross profit Rs m8324,722 0.3%  
Depreciation Rs m6110,266 0.6%   
Interest Rs m0634 0.0%   
Profit before tax Rs m28515,537 1.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m2,096349 600.6%   
Extraordinary Inc (Exp) Rs m-320-   
Tax Rs m62,965 0.2%   
Profit after tax Rs m2,34312,921 18.1%  
Gross profit margin %6.617.4 37.7%  
Effective tax rate %2.119.1 11.2%   
Net profit margin %185.99.1 2,042.4%  
BALANCE SHEET DATA
Current assets Rs m1,68996,837 1.7%   
Current liabilities Rs m48684,199 0.6%   
Net working cap to sales %95.48.9 1,071.9%  
Current ratio x3.51.2 302.0%  
Inventory Days Days21773 295.7%  
Debtors Days Days8198 83.0%  
Net fixed assets Rs m1,624102,552 1.6%   
Share capital Rs m534829 64.4%   
"Free" reserves Rs m5,960121,792 4.9%   
Net worth Rs m7,404122,621 6.0%   
Long term debt Rs m1045,449 1.9%   
Total assets Rs m8,010218,165 3.7%  
Interest coverage x950.725.5 3,727.2%   
Debt to equity ratio x00 31.7%  
Sales to assets ratio x0.20.7 24.2%   
Return on assets %29.36.2 470.8%  
Return on equity %31.610.5 300.3%  
Return on capital %31.312.9 242.6%  
Exports to sales %2.954.6 5.4%   
Imports to sales %28.99.4 308.6%   
Exports (fob) Rs m3777,520 0.0%   
Imports (cif) Rs m36413,274 2.7%   
Fx inflow Rs m3781,670 0.0%   
Fx outflow Rs m36526,355 1.4%   
Net fx Rs m-32855,315 -0.6%   
CASH FLOW
From Operations Rs m34621,444 1.6%  
From Investments Rs m-48-18,404 0.3%  
From Financial Activity Rs m-301-3,692 8.2%  
Net Cashflow Rs m-3-1,144 0.3%  

Share Holding

Indian Promoters % 64.0 25.5 251.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 5.4 3.7%  
FIIs % 9.7 35.3 27.5%  
ADR/GDR % 0.0 18.5 -  
Free float % 26.1 15.3 170.6%  
Shareholders   54,701 75,885 72.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC LTD With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  FULFORD INDIA  ALEMBIC PHARMA  ELDER PHARMA  

Compare ALEMBIC LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC LTD SHARE PRICE


Feb 16, 2018 (Close)

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC LTD 5-YR ANALYSIS

COMPARE ALEMBIC LTD WITH

MARKET STATS